INmune Bio Reveals New Findings, Says Analysis Of MRI Scans In Participants From Phase 1B Study Shows That Novel Gray Matter Biomarker Improved Following Three Months Of Treatment With XPro1595
Portfolio Pulse from Benzinga Newsdesk
INmune Bio has announced that analysis of MRI scans from participants in its Phase 1B study shows that a novel gray matter biomarker improved after three months of treatment with XPro1595.
July 11, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio's Phase 1B study results show improvement in a novel gray matter biomarker after three months of treatment with XPro1595, potentially indicating positive progress in their drug development.
The announcement of positive results from a Phase 1B study is typically a positive signal for biotech companies, as it indicates progress in the drug development process. This could potentially lead to increased investor confidence in INmune Bio, and therefore a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100